Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levofloxacin + tinidazole
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination involves **levofloxacin**, a fluoroquinolone antibiotic with broad-spectrum activity against Gram-negative bacteria and some Gram-positive bacteria, and **tinidazole**, an antiprotozoal and antibacterial agent effective against anaerobic bacteria and protozoa. The combination is used to treat infections such as pelvic inflammatory disease, where both aerobic and anaerobic pathogens are involved.
- Other names
- 左氧氟沙星 + 替硝唑
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on levofloxacin + tinidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levofloxacin + tinidazole.